Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UA19
- Development stage
- Preclinical
- Lead developer
- Wuhan Kangfude Biotechnology
01
Overview
UA19 is a preclinical drug candidate developed by the Kangfude Urolithiasis Institute (Wuhan Kangfude Biological Technology) for the treatment of hyperoxalemia and gout. The candidate is part of a pipeline focused on metabolic and urological health, though its specific modality and mechanism of action have not been disclosed. It is currently in the early stages of development, moving toward Investigational New Drug (IND) filing.
Beyond the preview
Go deeper on UA19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UA19.